Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT00349791Phase 3Completed
Phase 3, randomised, double-blind trial of Testosterone TEPI patch in hypoactive sexual desire disorder (HSDD) (2 arms), sponsored by Warner Chilcott. Primary endpoint: Change from baseline in the frequency of total satisfying sexual activity captured by the Sexual Activity Log (SAL) at 2 years. Started Jun 2002; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT00349791.